Stockscreener 앱 받기
0.8179
0.99%
0.008
시간 외 거래:
.75
-0.0679
-8.30%
전일 마감가:
$0.8099
열려 있는:
$0.87
하루 거래량:
101.89K
Relative Volume:
0.09
시가총액:
$19.16M
수익:
-
순이익/손실:
$-178.01M
주가수익비율:
-0.0982
EPS:
-8.326
순현금흐름:
$-7.87M
1주 성능:
+26.43%
1개월 성능:
-13.29%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.80
$0.92
1주일 범위
$0.63
$1.115
52주 변동 폭
$0.63
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
명칭
Lunai Bioworks Inc
전화
45 39179840
주소
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
0.8179 | 18.98M | 0 | -178.01M | -7.87M | -8.326 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lunai Bioworks Inc 주식(LNAI)의 최신 뉴스
Lunai Bioworks Faces Nasdaq Delisting After Bid Price Breach - TipRanks
Lunai Bioworks, Inc. Issues Letter to Shareholders - The Malaysian Reserve
LNAI Partners on Phase 2 Cancer Trial to Enhance Patient Outcomes - GuruFocus
LNAI Strengthens AI Platform for Biotech Innovations and Partner - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - Finviz
Lunai Bioworks (Nasdaq LNAI) launches AI oncology pilot - marketscreener.com
Lunai Bioworks (Nasdaq Lnai) Launches Ai Oncology Pilot - TradingView
Lunai Bioworks launches AI analysis of colorectal cancer trial data - Investing.com
Lunai Bioworks Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - marketscreener.com
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons - Finviz
Lunai Bioworks Highlights Sentinel AI Safeguard After Anthropic CEO Warning on AI Chemical and Biological Threats - natlawreview.com
Lunai Launches Sentinel AI Biosecurity Layer - Intellectia AI
AI safeguard Sentinel blocks novel chemical weapon designs at source - stocktitan.net
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery - The Malaysian Reserve
Lunai Bioworks launches alcohol use disorder drug discovery program By Investing.com - Investing.com Canada
Lunai Bioworks Expands NIH-Backed AI Platform Into Commercial Alcohol Use Disorder Drug Discovery - Nasdaq
LNAI Advances Drug Discovery Program for Alcohol Use Disorder - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into - GuruFocus
Lunai Bioworks Launches Alcohol Use Disorder Program Following Key Milestones - Intellectia AI
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - Montgomery Advertiser
Lunai Bioworks : JP Morgan Healthcare ConferenceMedTech Showcase Presentation - marketscreener.com
Lunai Bioworks (NASDAQ:LNAI) Raised to “Hold” at Wall Street Zen - Defense World
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - GuruFocus
AI drug startup in Parkinson's race draws attention as pharma talks heat up - Stock Titan
Lunai Bioworks: Year-End Partnering Momentum & Stock Setup - International Business Times
Lunai bioworks identifies three parkinsons disease subtypes By Investing.com - Investing.com South Africa
Lunai bioworks identifies three parkinsons disease subtypes - Investing.com
Lunai Bioworks identifies three Parkinson's disease subtypes - marketscreener.com
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market - Barchart.com
Ready to Jump After Recent Trade: Lunai Bioworks Inc (LNAI) - setenews.com
Lunai Bioworks to effect 10:1 reverse stock split - MSN
Lunai Bioworks (LNAI) Stock Analysis Report | Financials & Insights - Benzinga
Lunai Bioworks enters sales agreement with Dawson James SecuritiesSEC filing - marketscreener.com
Lunai Bioworks Enters Sales Agreement with Dawson James - TipRanks
Does Lunai Bioworks Inc (LNAI) offer a good opportunity for investors? - Setenews
Lunai Bioworks’ immune cell therapy shows tumor regression, wins first license - MSN
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy - MSN
Lunai Bioworks - The Pharma Letter
Lunai Bioworks lands first licensing deal for off-the-shelf cancer immunotherapy - The Pharma Letter
There is no way Lunai Bioworks Inc (LNAI) can keep these numbers up - Setenews
Lunai Bioworks Secures $3.1M in Private Placement - The Globe and Mail
Lunai Bioworks Inc (2Q50.MU) latest stock news and headlines - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Shares Decline Amidst New Licensing Agreement - Stocks Telegraph
Lunai Bioworks sells 3,133,333 shares in private financing deal - Stock Titan
LNAI Stock: Surging or Slipping? - StocksToTrade
Lunai Bioworks (LNAI) Stock: Plummets 14.2% Despite Breakthrough in Cancer Immunotherapy - parameter.io
Lunai Bioworks Shares Rise After Company Secures Licensing Intent for Dendritic Cell Therapy - marketscreener.com
Lunai Bioworks: Stock Surge or Bubble? - timothysykes.com
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy By Investing.com - Investing.com South Africa
LNAI's Groundbreaking Immune Cell Therapy Advances with Key Lice - GuruFocus
Lunai Bioworks Secures First Licensing LOI Following Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - MarketScreener
Lunai Bioworks Inc (LNAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):